Journal
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
Volume 24, Issue 11, Pages 553-556Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10815-007-9164-3
Keywords
integrin; implantation; endometriosis; in vitro fertilization; GnRH agonist
Ask authors/readers for more resources
Purpose Evaluate the incidence of aberrant endometrial integrin (alpha v beta(3) vitronectin) expression in patients at high risk for implantation defects. Materials and methods Retrospective case-control trial of 74 consecutive infertile patients with prior failed IVF cycles despite good embryo quality and/or endometriosis who underwent endometrial biopsy 9-11 days after an LH surge to assess the presence or absence of alpha v beta(3) vitronectin. Patients were separated into two groups for analysis based on the presence (Gr. A) or absence (Gr. B) of integrin expression. A subset of Gr. B patients (86.1%) was treated with a 2 month course of a GnRH agonist prior to IVF (Gr. B1). No Gr. A patients were so treated. Results Absent alpha v beta(3) vitronectin expression was noted in 48.6% of patients evaluated. A trend towards more severe endometriosis was noted in Gr. B (57.1 vs 31.5%). Responses to controlled ovarian hyperstimulation and IVF cycle outcomes including ongoing pregnancy rates were similar between Gr. B1 patients untreated Gr. A controls (55.6 vs 63.9%). Conclusions A high incidence of absent endometrial alpha v beta(3) vitronectin expression is noted in patients at increased risk for implantation defects. Prolonged GnRH agonist therapy prior to an IVF cycle resulted in outcomes similar to untreated controls with positive expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available